Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

NCT01902160 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

3

Enrollment

NIH

Sponsor class

Conditions

Recurrent Adult Hodgkin Lymphoma

Interventions

DRUG: Brentuximab Vedotin
OTHER: Laboratory Biomarker Analysis
DRUG: Temsirolimus

Sponsor

National Cancer Institute (NCI)